Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 8976 results

  1. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

    NICE guideline
    In development

  7. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTE10090 Expected publication date:  10 March 2027

    Health technology evaluations
    In development

  8. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  9. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  17 June 2026

    NICE guideline
    In development

  10. Teprotumumab for treating thyroid eye disease [ID6432]

    Deferred Reference number: GID-TA11531

    Technology appraisal guidance
    Deferred

  11. Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

    Awaiting development Reference number: GID-TA11835 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  14. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  15. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development